drugset / Trial / NCT00363077

Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate

NCT00363077

Phase 2 Completed 150 enrolled GlaxoSmithKline
RandomizedParallel-groupSingle-blindPrevention

Summary

The purpose of this study is to evaluate the immunogenicity and the safety of the candidate vaccine compared to Fluarix™ administered intramuscularly in elderly aged 60 years and above

Timeline

Start
2006-10-02
Primary completion
2006-11-01
Completion
2006-11-17

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK1247446A Vaccine Intramuscular
Comparator Influenza Virus Vaccine Vaccine Intramuscular

Indications